中国神经再生研究(英文版) ›› 2018, Vol. 13 ›› Issue (8): 1358-1359.doi: 10.4103/1673-5374.235226

• 观点:脊髓损伤修复保护与再生 • 上一篇    下一篇

脊髓再生成功与失败生物学

  

  • 收稿日期:2018-06-02 出版日期:2018-08-15 发布日期:2018-08-15

Perspectives on “the biology of spinal cord regeneration success and failure”

Philippa Mary Warren1, Amanda Phuong Tran2, Jerry Silver2   

  1. 1 School of Biomedical Sciences, University of Leeds, Leeds, UK;
    2 Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio, USA
  • Received:2018-06-02 Online:2018-08-15 Published:2018-08-15
  • Contact: Jerry Silver, Ph.D., jxs10@case.edu.
  • Supported by:

    PMW and JS were funded by the International Spinal Research Trust, Wings for Life, and the Craig H. Neilsen Foundation. APT and JS were funded by NINDS NS025713, The Hong Kong Spinal Cord Injury Fund, and The Brumagen/Nelsen Fund.

摘要:

orcid: 0000-0001-5002-2599 (Jerry Silver)

Abstract:

In our recently co-authored Physiological Reviews manuscript entitled “The biology of regeneration failure and success after spinal cord injury” , we sought to provide a comprehensive and up-to-date description of how the glial scar develops following spinal cord injury (SCI) to chronically inhibit axon regeneration. Our additional intention was to clarify some of the confusion in the field relating to an oversimplified view of the glial scar. We would like to take this opportunity to reiterate how the current body of literature, expounding details of the glial scar, has progressed beyond a simplified and outdated understanding of this structure as a mono-cellular arrangement consisting only of astrocytes that solely limit axon regeneration. Instead, our perception of the glial scar has evolved to acknowledge the nuances of this multi-cellular structure to one that is able to limit the expansion of inflammatory processes shortly following SCI and that also persists chronically to limit axon regeneration.Further, we would like to expand upon some of the details presented in the review by offering an outlook on the current state of the field and avenues for progression. This includes the specific role of chondroitin sulphate proteoglycan components in axonal growth and plasticity, and the current assessment of SCI at different stages post injury. As such, this perspective should be considered a companion piece to our original work,adding new insights from across the field from recent publications.